A Phase 2 interventional study of VP-102 in Common Warts, Common Warts (Verruca Vulgaris) and Human Papilloma Virus (HPV), sponsored by Verrica Pharmaceuticals Inc.. Not yet recruiting at 4 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Verrica Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Warts with a site in United States — 7 open to participants now, 10 under way, 4 of them phase 3. Warts · United States.
Among the 59 studies in Warts with a site in United States, this one is the 43rd largest by planned enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2026, is one of 23 in phase 2, and was the 59th registered.
172 studies on the registry are indexed under Warts; 36 are open to participants now.
Browse Warts studies →7 of the 59 studies in Warts with a site in United States are open now. Recruiting first, the newest first:
Verrica Pharmaceuticals Inc. · Sites in United States, Japan
Ages 2+
Verrica Pharmaceuticals Inc. · Sites in United States, Japan
Ages 2+
The Skin Center Dermatology Group · Sites in United States
Ages 8–18
Western Institute for Veterans Research · Sites in United States
Ages 18+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Warts studies recruiting now, 10 (53%) set no upper age limit and 9 (47%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 29 · Phase 3 13 · Phase 4 5
First in 2004; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 70 across 156 interventional studies indexed under Warts.
Median enrollment 80 across the 58 interventional studies, 950 across the 1 observational. Of the 44 that completed or were terminated, 27 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 59 have an industry lead sponsor. The 10 most frequent:
Verrica Pharmaceuticals Inc. is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Verrica Pharmaceuticals Inc. has 6 studies filed under Warts — fewer than ten, so there is no comparison to draw.
5 of the studies in Warts with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07246590Phase 3Verrica Pharmaceuticals Inc.Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) | 2026-11 |
| NCT07637734Phase 3Verrica Pharmaceuticals Inc.Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3) | 2027-05 |
| NCT07457918Phase 3Verrica Pharmaceuticals Inc.Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris) | 2027-11 |
| NCT07881952Verrica Pharmaceuticals Inc.Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5) | 2027-04 |
| NCT07806617Rush University Medical CenterIntralesional Gardasil-9 for the Treatment of Recalcitrant Warts | 2027-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 59 studies in Warts with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, open-label study (Study VP-CW-304; referred to as COVE-5 [Cantharidin and Occlusion in Verruca Epithelium 5]) to evaluate the safety and systemic exposure of YCANTH (VP-102) following a single 24-hour dermal application in subjects with common warts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Topical solution, which is a light violet to dark purple, slightly viscous liquid. Each single-use applicator contains 0.45 mL of 0.7% w/v cantharidin. VP-102 will be administered topically as a single application on Day 1 using no more than 2 applicators.
Combination Product: VP-102
YCANTH (VP-102) is supplied as a topical solution containing cantharidin 0.7% w/v in a single-use glass ampule applicator. The solution will be applied to the entirety of each common wart selected for treatment, including an approximate 1 to 2 mm margin of surrounding healthy skin. No more than 2 applicators may be used. Occlusive tape will be applied after the solution has dried and will remain in place overnight until removal at approximately 24 hours.
Proportion of subjects exhibiting systemic exposure to YCANTH (VP-102)
The proportion of subjects exhibiting systemic cantharidin exposure following a single application of YCANTH (VP-102), based on plasma samples collected before application of study drug and at 2, 6, and 24 hours after application.
Time frame: Predose, 2 hours, 6 hours, and 24 hours after study drug application
Incidence and severity of adverse events including local skin reactions
Number and percentage of subjects experiencing treatment-emergent adverse events (TEAEs), including local skin reactions (LSRs), and assessment of event severity.
Time frame: From study drug application on Day 1 through Day 21
Change from baseline in pulse rate
Change from baseline in pulse rate.
Time frame: Baseline through Day 21
Change from baseline in body temperature
Change from baseline in body temperature.
Time frame: Baseline through Day 21
Concomitant medication use
Number and percentage of subjects reporting concomitant medication use after study drug application.
Time frame: From study drug application on Day 1 through Day 21
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Apr 2027, 6 months later.
Of 18 phase 2 interventional studies under Warts, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 23. This study's planned 6 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VP-102
Verrica Pharmaceuticals Inc.